Low BMI-1 expression is associated with an activated BMI-1-driven signature, vascular invasion, and hormone receptor loss in endometrial carcinoma

por Engelsen, I B, Mannelqvist, M, Stefansson, I M, Carter, S L, Beroukhim, R, Øyan, A M, Otte, A P, Kalland, K H, Akslen, L A, Salvesen, H B
Publicado 2008

High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer

por Mauland, K K, Trovik, J, Wik, E, Raeder, M B, Njølstad, T S, Stefansson, I M, Øyan, A M, Kalland, K H, Bjørge, T, Akslen, L A, Salvesen, H B
Publicado 2011

High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors

por Engerud, H, Tangen, I L, Berg, A, Kusonmano, K, Halle, M K, Øyan, A M, Kalland, K H, Stefansson, I, Trovik, J, Salvesen, H B, Krakstad, C
Publicado 2014

Loss of GPER identifies new targets for therapy among a subgroup of ERα-positive endometrial cancer patients with poor outcome

por Krakstad, C, Trovik, J, Wik, E, Engelsen, I B, Werner, H M J, Birkeland, E, Raeder, M B, Øyan, A M, Stefansson, I M, Kalland, K H, Akslen, L A, Salvesen, H B
Publicado 2012

KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer

por Birkeland, E, Wik, E, Mjøs, S, Hoivik, E A, Trovik, J, Werner, H M J, Kusonmano, K, Petersen, K, Raeder, M B, Holst, F, Øyan, A M, Kalland, K-H, Akslen, L A, Simon, R, Krakstad, C, Salvesen, H B
Publicado 2012